Actively Recruiting
Comparing Oral Medications atogepant, Propranolol, and Topiramate for Preventing Migraine in Adults
Led by Mayo Clinic · Updated on 2026-10-19
1335
Participants Needed
37
Research Sites
39 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are comparing three medications used to prevent migraines in adults. This study evaluates the newer medication atogepant against two older drugs, topiramate and propranolol, to see which one works better and is easier to tolerate. Participants include adults aged 18 to 70 with migraine conditions defined by specific diagnostic criteria, including those with migraine with or without aura and chronic migraine. Participants will first track their migraine patterns using a daily headache diary for four weeks. Those who remain eligible after this period will be randomly assigned to take one of the study medicationsatogepant up to 60 mg daily, propranolol up to 160 mg daily, or topiramate up to 100 mg dailyfor twelve weeks. The study includes multiple visits at baseline, four weeks later for randomization, and then at weeks four, eight, twelve, twenty-four, and forty-eight post-randomization. During the study, participants provide data through headache diaries and research visits. Researchers measure the proportion of participants who respond to treatment, defined by a 50% or greater reduction in moderate to severe headache days during weeks 9 to 12 compared to before treatment. Secondary assessments include quality of life, headache impact tests, and medication-related side effects. The total participation can last up to 48 weeks with ongoing monitoring and data collection.
CONDITIONS
Brief Title
Comparative Effectiveness of Migraine Preventive Medications: The APT Comparison Study
Research Team
M
Michael R Leonard, MDiv
D
Dani C Smith, M.S.
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here